CNBC’s Becky Quick to Moderate High-Level CEO Panel at the 2026 NORD Rare Diseases & Orphan Products Breakthrough Summit

WASHINGTON, D.C. and NORWELL, Mass. — The National Organization for Rare Diseases (NORD®) has announced that CNBC “Squawk Box” co-anchor and “CNBC Cures” host Becky Quick will moderate a flagship rare disease CEO leadership dialogue during the upcoming NORD® Rare Diseases & Orphan Products Breakthrough Summit®. The high-profile panel will bring together the chief executive officers of BioMarin, Jazz Pharmaceuticals, and Otsuka, alongside NORD CEO Pam Gavin, to examine the complex mechanisms required to transform unprecedented scientific breakthroughs into tangible patient progress.

The collaborative session, officially titled “Next Decade of Rare Disease: A CEO Leadership Dialogue,” is scheduled for 11 a.m. ET on Monday, Oct. 26, in Washington, D.C. The panel anchors the second day of NORD’s comprehensive three-day annual summit, which runs from Oct. 25 through Oct. 27. Registration details and the full conference agenda are available at NORDSummit.org.

This year’s leadership dialogue arrives at a pivotal and defining juncture for the global rare disease community. Rapid advancements in science, genetics, and biotechnology are unlocking new diagnostic capabilities and treatment possibilities that would have been considered entirely unimaginable just a decade ago. However, industry stakeholders emphasize that scientific discovery alone does not guarantee that innovative therapies will successfully reach the individuals who urgently need them. Realizing the full potential of these emerging therapies will require robust regulatory frameworks, forward-thinking public policies, sustained capital investment, enhanced healthcare infrastructure, and modernized treatment delivery models that can keep pace with the velocity of innovation.

The conversation will directly address the overarching challenge of scale, exploring the leadership decisions, strategic investments, and cross-sector partnerships necessary to capitalize on this historic moment and advance a greater number of treatments across a broader spectrum of rare conditions.

The distinguished panel features executive leadership from global biopharmaceutical enterprises that maintain diverse rare disease portfolios, extensive development pipelines, and specialized experience in bringing complex therapies from the laboratory bench to the commercial market. Alongside these industry leaders, Pam Gavin will provide NORD’s independent, cross-disease patient and systemic perspective. Her participation will ground the business and scientific discussions in the diverse, unmet needs, clinical care hurdles, and profound access challenges experienced by patients and families navigating more than 10,000 distinct rare diseases.

Becky Quick brings decades of distinguished journalism experience covering global business, finance, and markets, as well as conducting high-level interviews with many of the world’s most influential corporate leaders. In addition to her professional expertise, Quick holds a deep, personal connection to the rare disease community as a parent of a child living with a rare condition. This dual perspective uniquely positions her to guide the dialogue, weaving together corporate strategy, economic realities, and patient-centric urgency to explore how industry leaders can maximize the impact of technological innovation and translate individual corporate breakthroughs into widespread clinical progress.

CNBC’s Becky Quick to Moderate CEO Leadership Dialogue on the Next Decade of Rare Disease at the NORD

“We are at an important moment for rare disease. Science is opening doors that would have been unimaginable even a decade ago, but discovery alone does not ensure those advances reach the people who need them,” said Pam Gavin, CEO of NORD. “Realizing that potential will require leadership across the rare disease ecosystem to remove barriers, keep pace with innovation and translate progress into better outcomes for more people across more rare diseases. That is why this conversation—and the Breakthrough Summit—matter right now.”

Now celebrating its 16th year, the NORD Rare Disease & Orphan Products Breakthrough Summit serves as a premier annual gathering, convening more than 900 leaders from across the entire rare disease ecosystem. Attendees include representatives from patient advocacy groups, biopharmaceutical companies, academic research institutions, regulatory agencies, and healthcare payers, all collaborating to address critical issues shaping the future of rare disease research, treatment development, public policy, clinical care, and patient access.

The comprehensive programming of the summit spans a wide array of vital topics, including federal health and regulatory priorities, emerging therapeutic platforms and technologies, venture investment and capital allocation, patient partnership models, and the systemic frameworks required to successfully shepherd medical breakthroughs through the translational pipeline from discovery to patient delivery.

In addition to the CEO leadership dialogue, the 2026 Breakthrough Summit will feature prominent keynote remarks and interactive panel discussions with senior federal health leaders. Among the notable public sector participants are Kyle Diamantas, J.D., Acting Commissioner of the U.S. Food and Drug Administration (FDA), and Jay Bhattacharya, M.D., Ph.D., Director of the National Institutes of Health (NIH). Their involvement underscores the vital public-private dialogue necessary to address the complex regulatory, scientific, and economic challenges inherent in rare disease therapeutic development.

The annual Breakthrough Summit is intentionally structured around the principle of cross-sector collaboration, emphasizing that the complex challenges facing the rare disease community are multifaceted and cannot be solved by any single organization, sector, or stakeholder group working in isolation. By bringing diverse voices together under one roof, the summit aims to foster actionable strategies and forge enduring partnerships that accelerate innovation and improve lives.

Founded in 1983, the National Organization for Rare Disorders (NORD) is a leading independent, nonpartisan, 501(c)(3) nonprofit organization dedicated to identifying, treating, and curing rare disorders through education, advocacy, research, and patient services. Representing the interests of over 30 million Americans living with rare diseases, NORD works in close partnership with more than 350 disease-specific member patient organizations to drive systemic progress across the rare disease landscape.

Evan Lee Salim

Penulis aktif di HypePress yang membagikan konten inspiratif, informasi terkini, dan gaya hidup untuk generasi muda.

Artikel Bermanfaat dan Menghibur Lainnya